Literature DB >> 15078277

The delivery of ivermectin (Mectizan).

G Burnham1, T Mebrahtu.   

Abstract

Over a comparatively short period of time, the development and distribution of ivermectin (Mectizan) has radically altered the consequences of infection with Onchocerca volvulus. To achieve this required the fostering of many partnerships and the development of new tools and methods. The long-term commitment of Merck, the World Bank and other sponsors, as well as governments and non-governmental organizations, has been crucial. Yet the enthusiasm with which communities have taken up the delivery of ivermectin among themselves is perhaps the greatest reason for the success of this programme. The present challenge is sustaining the methods that have brought success so far, and making them part of health services and disease control programmes in some of the world's most impoverished and unstable areas. A major part of this challenge is continuing the commitment to controlling onchocerciasis as memory of the disease is fading, and while the hope of elimination or eradication for most endemic countries remains distant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078277     DOI: 10.1111/j.1365-3156.2004.01211.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  9 in total

Review 1.  The effects of global health initiatives on country health systems: a review of the evidence from HIV/AIDS control.

Authors:  Regien G Biesma; Ruairí Brugha; Andrew Harmer; Aisling Walsh; Neil Spicer; Gill Walt
Journal:  Health Policy Plan       Date:  2009-06-02       Impact factor: 3.344

2.  Endectocides for malaria control.

Authors:  Brian D Foy; Kevin C Kobylinski; Ines Marques da Silva; Jason L Rasgon; Massamba Sylla
Journal:  Trends Parasitol       Date:  2011-07-03

3.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.

Authors:  Kevin C Kobylinski; Haoues Alout; Brian D Foy; Archie Clements; Poom Adisakwattana; Brett E Swierczewski; Jason H Richardson
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

4.  Assessment of the scope and practice of evaluation among medical donation programs.

Authors:  Alisa M Jenny; Meng Li; Elizabeth Ashbourne; Myron Aldrink; Christine Funk; Andy Stergachis
Journal:  Global Health       Date:  2016-11-04       Impact factor: 4.185

5.  Field-Based Evidence of Single and Few Doses of Annual Ivermectin Treatment Efficacy in Eliminating Skin Microfilaria Load after a Decade of Intervention.

Authors:  Hudu O Osue
Journal:  Ethiop J Health Sci       Date:  2017-03

Review 6.  Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.

Authors:  Zheng Yao Low; Ashley Jia Wen Yip; Sunil K Lal
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-10-20       Impact factor: 5.187

7.  Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP.

Authors:  Panos Kanavos; Sotiris Vandoros; Pat Garcia-Gonzalez
Journal:  Global Health       Date:  2009-12-31       Impact factor: 4.185

8.  Epidemiology and psycho-social aspects of onchocercal skin diseases in northeastern Nigeria.

Authors:  Ikem Chris Okoye; Celestine Oe Onwuliri
Journal:  Filaria J       Date:  2007-12-03

9.  The future of onchocerciasis control in Africa.

Authors:  Catherine Hodgkin; David H Molyneux; Adenike Abiose; Bernhard Philippon; Michael R Reich; J Hans Remme; Bjorn Thylefors; Mamadou Traore; Karen Grepin
Journal:  PLoS Negl Trop Dis       Date:  2007-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.